GlaxoSmithKline plc (NYSE:GSK) Weekly Ratings as of May 3, 2018

May 3, 2018 - By Anthony Rauscher

GlaxoSmithKline plc (NYSE:GSK) Corporate Logo

GlaxoSmithKline plc (NYSE:GSK) Ratings Coverage

Total analysts of 5 have positions in GlaxoSmithKline (NYSE:GSK) as follows: 4 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 80%. Since November 27, 2017 according to StockzIntelligence Inc GlaxoSmithKline has 6 analyst reports. The company rating was upgraded by UBS on Monday, November 27. On Wednesday, February 14 the rating was maintained by Cowen & Co with “Hold”. On Tuesday, January 16 the stock of GlaxoSmithKline plc (NYSE:GSK) earned “Buy” rating by Barclays Capital. On Wednesday, April 4 the stock of GlaxoSmithKline plc (NYSE:GSK) has “Buy” rating given by BNP Paribas. On Monday, December 11 the stock has “Hold” rating by Cowen & Co. Listed here are GlaxoSmithKline plc (NYSE:GSK) PTs and latest ratings.

04/04/2018 Broker: BNP Paribas Rating: Buy Upgrade
14/02/2018 Broker: Cowen & Co Rating: Hold New Target: $40.0 Maintain
16/01/2018 Broker: Barclays Capital Rating: Buy Upgrade
11/12/2017 Broker: Cowen & Co Rating: Hold New Target: $38.0 Maintain
30/11/2017 Broker: Argus Research Rating: Buy New Target: $40.0
27/11/2017 Broker: UBS Rating: Buy Upgrade

Ticker’s shares touched $39.51 during the last trading session after 1.32% change.GlaxoSmithKline plc has volume of 2.58M shares. Since May 3, 2017 GSK has declined 10.07% and is downtrending. The stock underperformed the S&P 500 by 21.62%.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide.The firm is worth $96.58 billion. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.The P/E ratio is 45.21. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

GlaxoSmithKline plc (NYSE:GSK) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.